XBI 📈 SPDR S&P Biotech - Overview

The SPDR S&P Biotech ETF, listed on the NYSE ARCA under the ticker XBI, aims to replicate the performance of the S&P Biotechnology Select Industry Index. To achieve this, the fund utilizes a sampling strategy, which involves investing a significant portion of its total assets in the securities that comprise the index. Specifically, the fund allocates at least 80% of its total assets to these securities, providing investors with exposure to the biotechnology segment of the S&P Total Market Index. This index is a subset of the broader S&P TMI, focusing on companies that are primarily engaged in the biotechnology industry.

The S&P Biotechnology Select Industry Index is designed to represent the biotechnology segment of the US equity market. The index includes companies that are involved in the research, development, and distribution of biotechnology products, as well as those that provide related services. By tracking this index, the SPDR S&P Biotech ETF provides investors with a diversified portfolio of biotechnology stocks, offering a way to gain exposure to this sector. The fund is listed in the United States and has the ISIN code US78464A8707, categorizing it as a health-focused ETF.

As an exchange-traded fund (ETF), the SPDR S&P Biotech ETF offers investors the benefits of diversification, liquidity, and transparency. The fund's holdings are disclosed daily, allowing investors to see exactly what they own. Additionally, the ETF's structure allows it to be traded on an exchange, providing investors with the flexibility to buy and sell shares throughout the trading day. For more information about the fund, investors can visit the website of the fund's issuer, which can be found at http://www.spdrs.com.